# To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

> **NCT04582539** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 22 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Multiple Myeloma
- Anemia

## Interventions

- **DRUG:** INCB000928

## Key facts

- **NCT ID:** NCT04582539
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-19
- **Primary completion:** 2024-08-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Strategic Business Decision
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582539, "To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT04582539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*